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Abstract 
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening complication 
of gemcitabine treatment. Since the approval of this nucleoside analog for the treatment 
of pancreatic cancer by the FDA in 1996, reported incidence varies from 0.015 to 1.4%. 
The classic ‘pentad’ describing the disease process (fever, hemolytic anemia, 
thrombocytopenia, neurological complications and renal impairment) is not always 
present to the same extent in every patient. Here, we present a rare case of TTP 
associated specifically with gemcitabine treatment, and further, we briefly discuss the 
manifestations, treatment options and outcomes related to the complication. In our 
opinion, it is important to realize that as the indications for the use of gemcitabine 
increase and its use becomes more widespread, TTP and other disorders on the spectrum 
of thrombotic microangiopathies are important considerations to remember in patients 
with worsening anemia and thrombocytopenia. New onset or exacerbation of underlying 




Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening condition 
with significant morbidity and mortality associated with the disease [1]. Prior to the 
1960s, the mortality numbers reporting TTP were as high as 77% [2]. The classic ‘pentad’ 
describing the disease process (fever, hemolytic anemia, thrombocytopenia, neurological 
complications and renal impairment) is not always present to the same extent in every 
patient. Of the causes associated with TTP, drugs, especially chemotherapeutic agents, are 
one of them. Early identification of TTP in such circumstances is essential in improving 
survival and instituting early treatment. Here, we present a rare case of TTP associated 
specifically with gemcitabine treatment, and further, we briefly discuss the manifestations, 
treatment options and outcomes related to the complication.  
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A 68-year-old woman with a past medical history significant for stage IIIB non-small cell lung 
cancer diagnosed 2 years ago presented to the Emergency Department with complaints of fever and 
headache 3 days after receiving a cycle of chemotherapy. 
With respect to her oncological history, she was originally treated with carboplatin, taxol (paclitaxel) 
and avastin (bevacizumab). In 2009, she showed progression of disease and was started on tarceva 
(erlotinib), and then switched to Alimta. However, following 8 cycles of Alimta (pemetrexed), a follow-
up computed tomography (CT) scan showed progression of disease, which is being treated with 
gemcitabine (Gemzar) since July 2010, showing no major complications and a stable malignancy. 
Apparently, after the cycles of chemotherapy, she used to have mild headaches and occasionally fever 
lasting for one or two days; however, symptoms related to her last cycle of chemotherapy 3 days ago 
were different. She described the pain as diffuse, sudden in onset, aching in nature and as the ‘worst’ 
headache she had ever had. Associated symptoms included fever (38.4°C, 101.1°F) on presentation, 
some neck pain/stiffness and eye discomfort/photophobia. Her vital signs otherwise were stable on 
presentation except for a systolic and diastolic blood pressure of 145–185 and 75–94 mm Hg, 
respectively. Of note, the patient was not hypertensive prior to admission and her only medical 
problems were mild depression and cervical cancer for which she had undergone curative surgery 40 
years ago. 
Initially, suspecting a possible viral versus bacterial meningitis, a lumbar puncture was instantly 
performed. However, the results were not suggestive of meningitis, and CSF parameters were within 
normal limits. The patient’s hemoglobin/hematocrit levels were noted to have trended down from a 
baseline of 9.3 g/dl (28.5%) to 8.4 g/dl (25.8%). Thrombocytopenia worsened from 144 ×10
9/l on 
presentation to 107 ×10
9/l on day 2 of admission. 
A literature review of side effects associated with gemcitabine showed that gemcitabine has the 
potential, though rarely, to cause microvascular angiopathy leading to hemolytic uremic syndrome 
(HUS), TTP, malignant hypertension and other related diseases. 
Given concerns for hemolysis and possible TTP in our patient, a peripheral smear was examined, 
which did show presence of schistocytes. Hemolysis laboratories also confirmed intravascular hemolysis 
(a high LDH of 437 IU/l and haptoglobin <4 mg/dl), for which the hematology department was 
promptly consulted. The patient was urgently started on plasmapheresis the same day and is undergoing 
daily plasmapheresis with monitoring of LDH, haptoglobin, hemoglobin, hematocrit and platelet counts 
along with her renal function. Table 1 highlights some of the typical findings reported in patients with 
gemcitabine-associated TTP and the findings seen in our patient.  
Discussion 
TTP is a rare and life-threatening complication of gemcitabine treatment. Since the 
approval of this nucleoside analog for the treatment of pancreatic cancer by the FDA in 
1996, reported incidence varies from 0.015 to 1.4% [3]. Endothelial cell injury is thought 
to be the postulated mechanism behind gemcitabine-induced TTP. The downstream 
effects from the endothelial dysfunction, including release of nitric oxide and von 
Willebrand factor, and increased levels of tissue plasminogen activator, thrombomodulin, 
and plasminogen activator inhibitor, are described to promote the development of TTP 
[4]. With the use of this drug becoming more common, gemcitabine-induced thrombotic 
microangiopathy (TMA) is increasingly being recognized, and TTP and HUS are 
considered disorders on the same spectrum of the disease process [5]. As is known, renal 
dysfunction tends to be the hallmark of HUS, whereas neurological complications tend to 
dominate in TTP [6].  
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According to the excellent review by Zupancic et al. [3] on gemcitabine-associated 
TTP, the complication appears to be dose related and is seen more in individuals with a 
cumulative dose of 20,000 mg/m
2 and when the number of doses exceeds 18. A review of 
our patient’s chemotherapy records revealed that she had received 13 doses of 
gemcitabine prior to presentation and that she was in the 8th month of therapy. Usually, 
the complication is rarely seen before the 7th month of therapy [7]. Of note, however, 
TTP can be seen earlier in individuals who are on multiple other chemotherapeutic agents 
associated with the development of the complication. While mitomycin and cisplatin have 
been classically implicated with TTP, other chemotherapeutic agents are also associated 
with this complication [8]. Table 2 outlines some of the chemotherapeutic and other 
classes of drugs associated with the development of TTP. 
A very interesting observation seen in patients who develop TTP specifically due to 
gemcitabine is either the development of new hypertension or difficulty in controlling 
blood pressure and/or increment in the number of antihypertensive medications in 
patients who have already been diagnosed with hypertension [9]. In a review of all cases 
with gemcitabine-associated TMA diagnosed at Partners Healthcare System (Boston, 
Mass., USA) between January 1997 and February 2002, apparently the patients’ blood 
pressure readings were noted to increase at least one week prior to symptoms onset. 
Moreover, 3 out of 9 patients had symptoms onset 6–10 weeks after the detection of the 
elevated blood pressures [9]. Thus, patients on gemcitabine should be frequently 
monitored for any changes in their blood pressure from baseline, since it may be a 
predictor of potentially dramatic microvascular complications in the near future. 
Moreover, in some series, the development of hypertension was also a marker for poor 
prognosis/outcome [5]. 
Treatment options employed and outcomes highlighted in the series of case reports 
have been variable and range from discontinuation of gemcitabine to only the 
employment of plasmapheresis and use of steroids along with control of blood pressure 
with antihypertensive medications. Some case reports have also highlighted a potential 
role of the anti-CD20 antibody rituximab in the treatment of TTP/HUS [8]. 
Plasmapheresis, however, appears to be the mainstay along with drug cessation in the 
treatment of gemcitabine-induced TTP, with most patients requiring at least 8–12 
treatments. Complications associated with the procedure itself, including line sepsis and 
hemorrhage from line insertion, thrombosis and mortality documented in patients 
receiving plasmapheresis should always be kept in mind [10]. 
Conclusions 
As the indications for the use of gemcitabine increase and its use becomes more 
widespread, TTP and other disorders on the spectrum of TMAs are important 
considerations to remember in patients with worsening anemia and thrombocytopenia. 
New onset or exacerbation of underlying hypertension may provide a clue to diagnose the 
disease entity earlier in this subgroup of patients.  
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Table 1. Comparison of findings noted in our patient and findings of patients with gemcitabine-
induced TTP 
Findings in gemcitabine-induced TTP    Findings in our patient 
New onset or worsening of hypertension noted specifically with 
gemcitabine-induced TTP; it is thought to represent underlining renal 
microvascular disease/damage and heralds the onset of TTP in 
patients treated with gemcitabine 
  Patient did not have any diagnosis of hypertension; 
noted to have blood pressures as high as 185/94 mm Hg 
on presentation, which increased to 204/100 mm Hg 
later during her hospital course, requiring multiple 
anti-hypertensives 
Fever   Fever 
Neurological symptoms    Severe headache and photophobia on presentation 
Microangiopathic hemolytic anemia    Microangiopathic hemolytic anemia 
Schistocytes present on peripheral smear    Schistocytes present on peripheral smear: 1+ 1–5%/hpf 
Increased LDH    Increased LDH: 437 IU/l, increased to 706 IU/l later 
Decreased haptoglobin    Decreased haptoglobin: <4 mg/dl 
Thrombocytopenia    Patient’s platelet number increased to 266 ×10
9/l in 
January, and rapidly decreased from 144 → 107 → 99 
×10
9/l prior to the start of plasmapheresis. The lowest 
platelet number decreased to 37 ×10
9/l 
Some degree of renal dysfunction    Some degree of renal dysfunction 
Increased BUN/Cr    BUN increased from 8 → 10 → 15 mg/dl despite i.v. 
boluses and continued hydration; Creatinine level is 1.1 
mg/dl; GFR decreased from 55 to 49 ml/min/1.73 m
2. 
Creatinine worsened to 1.9 mg/dl during her hospital 
course 
Mild proteinuria    2+ (~100 mg/dl or 0.5–1 g/day) protein on dipstick 
Mild hematuria    2+ (positive) blood on dipstick; 15–20 red blood 
cells/hpf on microscopy 
PT/PTT normal    Normal 
Fibrinogen normal     Normal 
Reticulocyte count (unreliable in setting of chemotherapy-induced 
TTP; most commonly low) 
  Reticulocyte count 0.4%; absolute reticulocyte count 
0.010 ×10
12/l; low 
Increased premature precursors    High nucleated red blood cells; 94.4% neutrophils  
Deficiencies of ADAMTS-13 (noted only in 13% of patients, thereby, 
representing a different mechanism) 
  94% (normal >68%) 
Pulmonary symptoms    Not present in our patient initially; however, when she 
received packed red blood cells for her worsening 
anemia, she developed pulmonary edema (which is  
also seen in patients with TTP when they receive 
transfusions. Transfusion-related acute lung injury and 
acute respiratory distress syndrome may also develop; 
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Table 2. Drugs associated with the development of TTP 
Chemotherapeutic drugs  
commonly associated  
with TTP 
Chemotherapeutic drugs  
less commonly associated  
with TTP/case reports 
Other drugs associated with TTP 
Mitomycin C (4–15%)  Fluorouracil Quinine 
Cisplatin (2–6%)  Dacarbazine  
  Doxorubicin  Estrogen-containing oral contraceptives 
  Carboplatin  
  Oxaliplatin  
  Lomustine  Immunosuppressive agents  
  Bleomycin –  Cyclosporine   
  Vinblastine –  Tacrolimus 
  Medroxyprogesterone –  Sirolimus 
  Tamoxifen  
  Chlorozotocin Antiplatelet  drugs 
  Zinostatin –  Ticlopidine 
  Carmustine –  Clopidogrel 
  Tretinoin  
  Pentostatin Antiviral  agents 
  Estramustine –  Valacyclovir   
  Cytarabine  
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